Welcome to the site FIP Warriors, where we would like to bring you information about the treatment of FIP - a disease that until recently meant a death sentence for every cat that broke out. The hope of rescue came with a nucleoside analog GS-441524 developed by Gilead Sciences, hence GS in the code designation.
The discovery of FIP treatment was the culmination of a 50-year study by Dr. Pedersen and his team. In 2017, they took place at UC Davis under his leadership field trials using a new substance that was still known at the time as EVO984. As a result, their efficacy in the treatment of this dreaded disease was clearly confirmed. And so the stories of FIP fighters began to be written, who finally began to win over the disease.
On this website you will find a lot of information about FIP, but also its diagnosis and treatment. You can also read here 119 articles, translated into Slovak from foreign press. And, of course, there is an overview drugs.
At the end of 2021, a drug was approved for the treatment of Covid-19 Molnupiravir, sold in the Czech Republic and Slovakia under the trade name Lagevrio. Although no clinical trial has been performed to treat FIP, it has been used many times in practice and its efficacy is evident.
In addition, Anivive is working to approve a protease inhibitor called GC376which was the subject of clinical study for the treatment of FIP as early as 2016 and proved to be effective mainly in the treatment of wet and dry FIP without eyepieces and neurological symptoms.
Given that the owner of the Gilead Sciences patent is not interested in launching GS-441524, and especially in the case of Covid-19, he preferred Remdesivir, it is very questionable when and if at all in the foreseeable future we will receive legal treatment with GS-441524. . All medicines on the market are thus produced without the consent of Gilead and come from the Chinese market. We would like to draw your attention to the fact that if you use any information you learn here in practice, you do so at your own risk. By staying on this site, you agree to this basic condition. we thank you
EN 
SK